- Business
- Maider Medical Industry Equipment Co. Ltd. (688310.SS) engages in the research, development, production, sale, and service of intelligent automation equipment for medical consumables, primarily serving the healthcare equipment and supplies industry in China and internationally. Founded in 2003 and headquartered in Taizhou City, Zhejiang Province, China, the company offers comprehensive solutions including blood purification equipment such as automatic assembly machines for hemodialyzers, AV fistula needles, peritoneal dialysis pipelines, powder barrels, hollow fiber membrane spinning lines, hemoperfusion cartridges, pre-filled flushing syringes, and dialysis bloodlines; infusion solutions comprising automatic assembly machines for IV catheters and sets; transfusion solutions including disposable transfusion sets and leukocyte filters; biological reagents equipment like PCR automatic packaging systems; blood collection solutions for blood lancets, safety blood collection needles, and vacuum blood collection tubes; blood glucose solutions for insulin pens, pen needles, and syringes; in vivo intervention solutions for biopsy needles; respiration solutions for sputum suction catheters; anesthesia solutions for extension sets and spinal anesthesia needles; urinary system solutions for urinary catheters; and other combined products such as pre-filled and safety syringes, tube extrusion, and cutting machines. The company operates through three major business systems: intelligent equipment, IO4-enabled data management software, and process development, targeting global medical enterprises including Fresenius, Terumo, Shandong Weigao, and Kindly, with over 3,000 customized solutions delivered worldwide. In recent developments, Maider Medical reported a net loss in the first quarter of 2025 amid a 45.87% year-over-year revenue decline to 40.18 million yuan, announced a 38.6 million yuan capital increase for subsidiary Maideshun introducing new investors, completed a share repurchase of 2.09 million shares (1.26% of total capital) by January 2025, elected Lin Junhua as board chairman, and plans active participation in 2025 exhibitions including ME Expo, ARAB HEALTH, MEDICA, and COMPAMED to expand its medical automation presence.